[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Biotech Healthcare Holding Gmbh\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100610825","a-planned-study-at-multiple-sites-is-being-done-to-compare-the-results-of-two-types-of-trifocal-toric-intraocular-lenses-used-in-cataract-surgery-100610825",false,"NCT07232615","A Planned Study at Multiple Sites is Being Done to Compare the Results of Two Types of Trifocal Toric Intraocular Lenses Used in Cataract Surgery","A Prospective, Multicenter Clinical Study Comparing Outcomes of Two Trifocal Toric Intraocular Lens","Inclusion Criteria:\n\n1. Age of patient \\>21 Years\n2. Patient diagnosed with cataract.\n3. Patient must have preoperative regular corneal astigmatism between 0.75 to 4.5 D as per corneal topography or keratometry\n4. Calculated IOL power is within the range of investigational IOLs.\n5. Patient willing to sign inform consent form.\n6. Clear intraocular media other than cataract.\n7. Female participants of childbearing potential must be willing to ensure that they use effective contraception during the study.\n\nExclusion Criteria:\n\n1. Previous intraocular or corneal surgery.\n2. Traumatic cataract\n3. Pregnancy (as stated by patient) or lactation.\n4. Concurrent participation in another drug or device investigation.\n5. Irregular astigmatism.\n6. Patient receiving chlorquine treatment.\n7. Subjects with any systemic disease that could increase operative risk or confound the outcome.\n8. Active ocular disease in the operative eye other than cataract.\n9. Vulnerable subjects as defined in section 12.3.9.\n10. Corneal Astigmatism \\> 4.5 D","ALL","21 Years",{"count":19,"type":20},138,"ESTIMATED","INTERVENTIONAL",[23],"NA","To evaluate the clinical outcomes and patient satisfaction of two commercially available trifocal toric intraocular lenses Primary Objective: To compare the distance-corrected intermediate visual acuity between the two trifocal toric intraocular lenses. Secondary Objectives: To assess and compare the safety of two trifocal toric intraocular lenses.",[26,27,28],"Presbyopia Correction","Astigmatism","Cataract","RECRUITING","2025-11-14",{"date":32,"type":33},"2025-11-18","ACTUAL",{"date":35,"type":33},"2021-11-22",{"date":37,"type":20},"2027-02",{"name":39,"class":40},"Biotech Healthcare Holding Gmbh","INDUSTRY",6,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":63,"locationsCount":64},"100580638","a-prospective-randomized-clinical-study-of-two-phakic-toric-implantable-lenses-100580638","NCT06839898","A Prospective, Randomized Clinical Study of Two Phakic Toric Implantable Lenses","A Prospective, Randomized Clinical Study of Two Phakic Toric Implantable Lenses to Compare Outcomes in Patients With Moderate to High Myopia and Astigmatism","Inclusion Criteria:\n\n* Patients 21 years old or older.\n* Calculated IOL Power is within the range of the investigational IOLs\n* Corneal Cylindrical error within the range defined in the clinical investigation plan\n* Subject has monocular UCVA 0.5 LogMAR or worse\n* Subject has had a stable refraction (±0.5D; ±1.0D for higher refractive errors), as expressed by manifest refraction spherical equivalent (MRSE) for a minimum 12 months prior to surgery, verified by consecutive refractions and\u002For medical records or prescription history.\n* Subject, who is a current contact lens wearer, needs to demonstrate a stable refraction (±0.5D) expressed as MRSE, on two consecutive examination dates and stability of the refraction is determined by the following criteria:\n\n  1. Contact lenses were not worn for at least 2 weeks or 3 days prior to the first refraction.\n  2. Two refractions were performed at least 7 days apart.\n* Subject, who is expected to have residual postoperative cylindrical refractive error of ≥1D, has been given the opportunity to experience his\u002Fher best spectacle vision with the anticipated correction.\n* Expected dilated pupil size at least large enough to visualize the axis marking.\n* Patients willing to attend all follow-up appointments\n* Patients must sign and be given a copy of the written Informed Consent form\n\nExclusion Criteria:\n\n* Subject with acute and chronic disease or illness that would increase the operative risk or confound the outcomes of the evaluation.\n* Subject taking systematic medication that can confound the outcome of the study or increase the risk to the subject\n* Subject with ocular condition that may predispose the subject to future complications\n* Subject with previous intraocular or corneal surgery\n* Subject with less than the minimum endothelial cell density 2000 cells\u002Fmm² at the time of enrollment\n* Pregnant or planning to become pregnant, or is lactating during the course of the evaluation\n* Other condition associated with fluctuation of hormones\n* ACD measured from the endothelium lower than 2.8 mm\n* Concurrent participation in another drug or device evaluation.\n* Any cataract of any grade.\n* Coefficient of variation of endothelial cell area \\>0.45\n* Percent Hexagonality of endothelial cell shape ≤ 45%\n* Monocular subject\n* Vulnerable subjects as defined in section 12.3.10",{"count":50,"type":20},172,[23],"Primary Objective: To compare the efficacy and the residual refractive error of EYECRYLTM Phakic toric versus Visian® Toric ICL in moderate to high myopic patient with co-existing astigmatism. Secondary Objectives: To evaluate and compare the safety of EYECRYLTM Phakic toric versus Visian® Toric ICL in moderate to high myopic patients with co-existing astigmatism.",[54,55,56],"Myopia, Moderate","Myopic Astigmatism","Myopia, Degenerative","2025-02-17",{"date":59,"type":33},"2025-02-21",{"date":61,"type":33},"2021-10-10",{"date":37,"type":20},{"name":39,"class":40},4,""]